Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing
about
Animal models for the study of HCVEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manAdvances in Engineered Liver Models for Investigating Drug-Induced Liver InjuryAssessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound.Long-term culture of human liver tissue with advanced hepatic functions.A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.When will resistance be futile?Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicityHumanized thymidine kinase-NOG mice can be used to identify drugs that cause animal-specific hepatotoxicity: a case study with furosemide.Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice.Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Regulatory Forum Opinion Piece*: Use and Utility of Animal Models of Disease for Nonclinical Safety Assessment: A Pharmaceutical Industry Survey.Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters.Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.Blocking Zika virus vertical transmission.Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.Humanized Mice as Unique Tools for Human-Specific Studies.Addressing the selectivity and toxicity of antiviral nucleosides.
P2860
Q26797836-1865B8E9-2F48-46D7-8A8D-ABD13ECEC0D0Q28069617-5BCD42ED-A59F-4C15-86A9-EA454416DA08Q28077505-A9229E76-26C3-4BC7-859C-F5574E80A1CDQ31002556-A9D5B915-C1FC-4788-B8D0-727F5B875968Q33752322-DD613EE8-49AB-4CCD-B766-E45C90CF85C9Q33849042-BA2AFF3C-C27B-43E9-A92B-FDF6779E279EQ34715457-4E7C9927-9204-4C64-B5C6-0A37CAC12F9AQ34946723-9464E9CD-4533-4693-B702-EE9157242D76Q35745207-BB5C96C3-B4AF-45B7-BAD8-8E53471FE392Q35757391-EE953310-0566-4D7F-B276-2D5225213410Q35819331-C1501C2E-94F8-42D7-A5D9-F931A1296FF8Q35917180-FDD540D9-B53C-4650-B013-99EAED3C82D3Q37402299-C23B6CFF-E75F-4FCD-AE0A-1E82DFCC54CFQ38255685-A9971ACA-D6D3-4D04-AC54-6132996ECA11Q38774776-2CA84BFB-16C7-4451-8427-68A9666142F8Q38870693-FA1893F9-CF9E-45C3-9524-3BB548E673A2Q39366146-1E40F903-06EC-42A5-B624-1A89D496E9AFQ39656279-C56DCC17-481C-4AC9-8254-B67B87B3E27BQ40398599-2610252D-5B30-46B6-B125-2FEC6BFAC44CQ40732028-0D34603A-A314-4E16-A851-15DF357C4A70Q40770241-D24CF72D-11BF-4838-8421-86F66A5546A3Q42495773-7D11DE8F-ED43-4132-80B3-78EABD4712B6Q47385711-390F3EEE-7B75-4357-98C2-C1FAFDDF2268Q47547159-62DD6E04-4329-47D4-9AB5-EF76B36FF449Q48453320-4D508F97-A980-46E2-9FE7-09765E4428BBQ49489377-92666B87-3AD7-4A8C-BDD2-E5507B4A21CAQ49663116-65DD3E31-94A0-4A0E-90FA-629D4E51EA08Q50146682-25DA1F2F-08B4-4061-982F-10644B0F0291Q52657691-FB8D5DF9-CC8B-4565-97D9-548CFD55F7F9
P2860
Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fialuridine induces acute live ...... oxicity prior to human testing
@ast
Fialuridine induces acute live ...... oxicity prior to human testing
@en
Fialuridine induces acute live ...... oxicity prior to human testing
@nl
type
label
Fialuridine induces acute live ...... oxicity prior to human testing
@ast
Fialuridine induces acute live ...... oxicity prior to human testing
@en
Fialuridine induces acute live ...... oxicity prior to human testing
@nl
prefLabel
Fialuridine induces acute live ...... oxicity prior to human testing
@ast
Fialuridine induces acute live ...... oxicity prior to human testing
@en
Fialuridine induces acute live ...... oxicity prior to human testing
@nl
P2093
P2860
P3181
P1433
P1476
Fialuridine induces acute live ...... oxicity prior to human testing
@en
P2093
Gary Peltz
Haili Zhang
Jeffrey Glenn
Marylin Masek
Ming Zheng
Sachiko Nishimura
Sara A Michie
Toshi Nishimura
Ying-Ying Guo
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001628
P407
P577
2014-04-01T00:00:00Z